Guardant Health (NASDAQ:GH) Sets New 1-Year High – Here’s Why

Guardant Health, Inc. (NASDAQ:GH) reached a new 52-week high on Tuesday . The company traded as high as $113.91 and last traded at $107.57, with a volume of 2356343 shares changing hands. The stock had previously closed at $110.17.

Guardant Health News Summary

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Company issued revenue guidance above consensus for Q4 and FY2025 (Q4 revenue guided to $280M vs. consensus ~$267.5M; FY revenue guided to $981M vs. consensus ~$968.3M). This directly supports near-term top-line expectations. Guardant Health guides Q4 and FY25 revenue above consensus
• Positive Sentiment: Preliminary, unaudited Q4 results align with guidance: ~ $280M revenue (up ~39% YoY) and ~79,000 oncology tests (up ~38% YoY). These operational trends validate growth momentum. Guardant Health Announces Preliminary Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: TRICARE added no‑copay coverage for Guardant’s Shield test for service members — a reimbursement/policy win that can boost adoption in a defined population and supports recurring test volume. Guardant Health (GH) Is Up 8.3% After TRICARE Adds No-Copay Shield Coverage For Service Members
• Positive Sentiment: Guggenheim raised its price target (from $85 to $115) and reiterated a Buy — analyst support that may influence sentiment and investor demand. Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH)
• Neutral Sentiment: Guardant presented at the 44th J.P. Morgan Healthcare Conference; the transcript provides management commentary and strategy detail but did not introduce new financial surprises. Use the presentation for channel/checkpoint color rather than immediate catalysts. Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Short-interest reporting in the data feed appears erroneous (shows 0 shares / NaN change). Currently no clear short-pressure signal from published data; treat the short-interest note as unreliable until confirmed by an exchange source.
• Negative Sentiment: An insider sold about $1.12M of GH stock — a modest negative signal that some investors interpret as insider profit-taking. Context (size vs. holding, reason) matters; on its own it may temper sentiment. Guardant Health (NASDAQ:GH) Insider Sells $1,124,274.48 in Stock

Analysts Set New Price Targets

Several brokerages have weighed in on GH. BTIG Research boosted their price objective on Guardant Health from $100.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 7th. Guggenheim increased their price target on shares of Guardant Health from $85.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Morgan Stanley raised their price target on shares of Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Wednesday, October 8th. Twenty-two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.81.

Guardant Health Stock Down 2.4%

The company’s fifty day simple moving average is $102.32 and its 200 day simple moving average is $73.89. The firm has a market capitalization of $13.56 billion, a PE ratio of -33.51 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. During the same period in the previous year, the company posted ($0.88) EPS. The company’s quarterly revenue was up 38.5% on a year-over-year basis. Equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling at Guardant Health

In other news, insider Chris Freeman sold 31,452 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.07, for a total transaction of $3,241,757.64. Following the sale, the insider owned 25,987 shares in the company, valued at approximately $2,678,480.09. The trade was a 54.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Helmy Eltoukhy sold 90,565 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the transaction, the chief executive officer owned 2,047,143 shares of the company’s stock, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 436,694 shares of company stock valued at $45,632,343. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Guardant Health

A number of hedge funds have recently made changes to their positions in GH. Alyeska Investment Group L.P. purchased a new stake in shares of Guardant Health in the 3rd quarter worth approximately $114,421,000. ARK Investment Management LLC boosted its holdings in Guardant Health by 100.4% in the second quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock worth $146,935,000 after acquiring an additional 1,414,381 shares in the last quarter. Norges Bank purchased a new stake in shares of Guardant Health in the second quarter worth $64,136,000. Franklin Resources Inc. increased its holdings in shares of Guardant Health by 78.2% during the second quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after acquiring an additional 1,018,144 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Guardant Health by 27.3% in the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after purchasing an additional 763,834 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.